By Scientia Professor Gregory John Dore

Books

, 2009, Hepatitis C: An Expanding Perspective, Dore GJ; Dore G; Lloyd AROLA, (eds.), IP Communications, East Hawthorn

Book Chapters

Hajarizadeh B; Martinello M; Dore G, 2021, 'HCV Elimination in Australia', in Hepatitis C: Epidemiology, Prevention and Elimination Volume 1, Springer, https://doi.org/10.1007/978-3-030-64649-3_11

Dore GJ; Martinello M, 2020, 'Global elimination of hepatitis C virus by 2030: The optimistic view', in Clinical Dilemmas in Viral Liver Disease, Second Edition, pp. 238 - 243, http://dx.doi.org/10.1002/9781119533481.ch40

Martinello M; Hajarizadeh B; Grebely J; Matthews G; Dore G, 2019, 'Cure and Control: What Will It Take to Eliminate HCV?', in Sofia M (ed.), HCV: The Journey from Discovery to a Cure: Volume II, Springer International Publishing, pp. 447 - 490, http://dx.doi.org/10.1007/7355_2018_56

Martinello MK; Grebely J; Dore G, 2017, 'Protease, polymerase and assembly inhibitors for the treatment of hepatitis C virus infection', in Kucers' The Use of Antibiotics A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition - Three Volume Set, CRC Press

Thein H-H; Dore GJ, 2010, 'Cognitive Function, Mood and Health-Related Quality of Life in Hepatitis C Virus-Infected Individuals', in Handbook of Disease Burdens and Quality of Life Measures, Springer New York, pp. 3299 - 3326, http://dx.doi.org/10.1007/978-0-387-78665-0_191

Grebely J; Dore GJ, 2009, 'Acute hepatitis C infection', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, IP Communications, East Hawthorn, pp. 230 - 253

Boesecke C; Dore GJ; Cooper DA, 2009, 'AIDS: Clinical Manifestations', in Encyclopedia of Life Sciences (eLS), John Wiley & Sons, Ltd., Chichester, pp. 1 - 10, http://dx.doi.org/10.1002/9780470015902.a0002237.pub2

Dore GJ; Temple-Smith M; Lloyd AROLA, 2009, 'Future challenges for hepatitis C', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, IP Communications, East Hawthorn, pp. 433 - 452, http://www.ipcommunications.com.au/

Matthews G; Dore GJ, 2009, 'HIV and hepatitis C co-infection', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, IP Communications, East Hawthorn, pp. 308 - 329

Loveday S; Dore GJ, 2009, 'Improving quality of life for people with hepatitis C', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, IP Communications, East Hawthorn, pp. 172 - 180

Dore GJ, 2009, 'Initial assessment and clinical monitoring of people with hepatitis C', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, IP Communications, East Hawthorn, pp. 156 - 169

Thein HH; Dore GJ, 2009, 'Natural history of hepatitis C virus infection', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, IP Communications, East Hawthorn, pp. 76 - 89

Dore GJ, 2009, 'Therapy decision-making for people with chronic hepatitis C', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, IP Communications, East Hawthorn, pp. 181 - 191

Nguyen VT; Dore GJ, 2008, 'Prevalence and epidemiology of hepatitis B', in Matthews G; Robotin M (ed.), B positive: All you wanted to know about hepatitis B: A guide for primary care providers, Australasian Society for HIV Medicine (ASHM), Darlinghurst, Australia, pp. 13 - 23, http://www.ashm.org.au/images/publications/monographs/b%20positive/b_positive-all_you_wanted_to_know.pdf

Dore GJ; Cooper DA, 2003, 'AIDS : Clinical Manifestations', in , Wiley, http://dx.doi.org/10.1038/npg.els.0002237

Dore GJ, 2001, 'Initial assessment and clinical monitoring of people with hepatitis C', in Crofts N; Dore G; Locarnini S (ed.), Hepatitis C: An Australian Perspective, IP Communications, Melbourne, pp. 129 - 139

Dore GJ, 2001, 'Natural history of hepatitis C infection', in Crofts N; Dore G; Locarnini S (ed.), Hepatitis C: An Australian Perspective, IP Communications, Melbourne, pp. 82 - 100

Dore GJ, 2001, 'Theapy decision-making for people with chronic hepatitis C', in Crofts N; Dore G; Locarnini S (ed.), Hepatitis C: An Australian Perspective, IP Communications, Melbourne, pp. 172 - 182

Correll PK; MacDonald MA; Dore GJ, 2000, 'Hepatitis C infection in indigenous communities in Australia', in Hepatitis C: Informing Australia`s Response, Commonwealth Department of Health and Aged Care, Canberra, pp. 47 - 60

Dore GJ, 2000, 'Natural history of hepatitis C virus infection', in Hepatitis C: Informing Australia`s Response, Commonwealth Department of Health and Aged Care, Canberra, pp. 95 - 118

MacDonald MA; Correll PK; Dore GJ, 2000, 'Occupational exposure to hepatitis C in health care settings', in Hepatitis C: Informing Australia`s Response, Commonwealth Department of Health and Aged Care, Canberra, pp. 119 - 135

Journal articles

McKetin R; Degan TJ; Saunders L; Nguyen L; Dore G; Shoptaw S; Farrell M; Degenhardt L; Kelly PJ; Turner A; Clare PJ; Dean OM; Arunogiri S; Colledge-Frisby S; Koeijers J; Goodman-Meza D; Sinclair B; Reid D; Hill H; Hayllar J; Christmass M; Cordaro F; Lundin R; Liaw W; Liu D; Holyoak E; Wu BTF; Keygan J; Kontogiannis A; Palmer L; Morrison C; Wrobel A; Hyland B; Byrne M; Russell S; Zahra E; Berk M, 2024, 'A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial', Trials, 25, http://dx.doi.org/10.1186/s13063-024-08238-y

Phetsouphanh C; Jacka B; Ballouz S; Jackson KJL; Wilson DB; Manandhar B; Klemm V; Tan HX; Wheatley A; Aggarwal A; Akerman A; Milogiannakis V; Starr M; Cunningham P; Turville SG; Kent SJ; Byrne A; Brew BJ; Darley DR; Dore GJ; Kelleher AD; Matthews GV, 2024, 'Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-47720-8

Bah R; Sheehan Y; Li X; Dore GJ; Grebely J; Lloyd AR; Hajarizadeh B; Bah R; Li C; Byrne M; Butler T; Musarurwa B; Hooshmand E; Simpson A; Alrayyani M; Price N; Groom M, 2024, 'Prevalence of blood-borne virus infections and uptake of hepatitis C testing and treatment in Australian prisons: the AusHep study', The Lancet Regional Health - Western Pacific, 53, http://dx.doi.org/10.1016/j.lanwpc.2024.101240

Marshall AD; Conway A; Cunningham EB; Valerio H; Silk D; Alavi M; Tillakeratne S; Wade A; Lam T; Zohrab K; Dunlop A; Connelly C; Cock V; Burns C; Henderson C; Christmass M; Dore GJ; Grebely J, 2024, 'A Pilot Randomised Controlled Trial Involving Financial Incentives to Facilitate Hepatitis C Treatment Uptake Among People Who Inject Drugs: ETHOS Engage Study', Viruses, 16, http://dx.doi.org/10.3390/v16111763

Ryan H; Dore GJ; Grebely J; Byrne M; Cunningham EB; Martinello M; Lloyd AR; Hajarizadeh B, 2024, 'Hepatitis C treatment outcome among people in prison: The SToP-C study', Liver International, 44, pp. 2996 - 3007, http://dx.doi.org/10.1111/liv.16074

Tillakeratne S; Pearson SA; Alavi M; Hajarizadeh B; Martinello M; Law M; George J; Amin J; Matthews G; Grebely J; Dore GJ; Valerio H, 2024, 'Trends in viral hepatitis liver-related morbidity and mortality in New South Wales, Australia', The Lancet Regional Health - Western Pacific, 51, http://dx.doi.org/10.1016/j.lanwpc.2024.101185

Maher L; Wand H; Heard S; Starr M; Zolala F; Kemp R; Cunningham P; Drummer H; Hellard M; Kaldor J; Dore G, 2024, 'Utilising integrated bio-behavioural surveillance (IBBS) to investigate declining hepatitis C antibody prevalence among people who inject drugs in the Australian Needle and Syringe Program Survey.', Int J Drug Policy, pp. 104576, http://dx.doi.org/10.1016/j.drugpo.2024.104576

Maher L; Wand H; Heard S; Starr M; Zolala F; Kemp R; Cunningham P; Drummer H; Hellard M; Kaldor J; Dore G, 2024, 'Utilising Integrated Bio-behavioural Surveillance (IBBS) to investigate declining hepatitis C antibody prevalence among people who inject drugs in the Australian Needle and Syringe Program Survey', International Journal of Drug Policy, 131, http://dx.doi.org/10.1016/j.drugpo.2024.104545

Marshall AD; Rance J; Dore GJ; Grebely J; Treloar C, 2024, 'Applying a stigma and time framework to facilitate equitable access to hepatitis C care among women who inject drugs: The ETHOS Engage Study', International Journal of Drug Policy, 129, http://dx.doi.org/10.1016/j.drugpo.2024.104477

Valerio H; Alavi M; Marshall AD; Hajarizadeh B; Amin J; Law M; Tillakeratne S; George J; Degenhardt L; Grebely J; Matthews GV; Dore GJ, 2024, 'Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia: A population-based study', Drug and Alcohol Review, 43, pp. 1080 - 1092, http://dx.doi.org/10.1111/dar.13688

Murdock NA; Alajaji NE; Schaefer R; Boone CA; Campo RE; Dore GJ; Gandhi M; Gorospe JR; Gulick RM; Hodder SL; Liu J; Rhee MS; Rooney JF; Vannappagari V; Wilkin T; Miller V, 2024, 'Long-acting HIV Treatments: Study Design, Logistics, and Access', Open Forum Infectious Diseases, 11, http://dx.doi.org/10.1093/ofid/ofae337

Broady TR; Valerio H; Alavi M; Wheeler A; Silk D; Martinello M; Conway A; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Treloar C; Grebely J, 2024, 'Factors associated with experiencing stigma, discrimination, and negative health care treatment among people who inject drugs', International Journal of Drug Policy, 128, http://dx.doi.org/10.1016/j.drugpo.2024.104468

Farrell M; Shahbazi J; Chambers M; Byrne M; Gholami J; Zahra E; Grebely J; Lintzeris N; Larance B; Ali R; Nielsen S; Dunlop A; Dore GJ; McDonough M; Montebello M; Weiss R; Rodgers C; Cook J; Degenhardt L, 2024, '96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial', International Journal of Drug Policy, 127, http://dx.doi.org/10.1016/j.drugpo.2024.104390

Valerio H; Marshall AD; Conway A; Treloar C; Carter L; Martinello M; Henderson C; Amin J; Read P; Silk D; Degenhardt L; Prain B; Alavi M; Dore GJ; Grebely J, 2024, 'Factors associated with hepatitis C testing, treatment, and current hepatitis C infection among men and women who inject drugs: The ETHOS engage study', International Journal of Drug Policy, 127, http://dx.doi.org/10.1016/j.drugpo.2024.104394

Farooq A; Valerio H; Wheeler A; Martinello M; Henderson C; Silk D; Degenhardt L; Read P; Dore GJ; Grebely J; Cunningham EB, 2024, 'Needle and syringe sharing among people who have recently injected drugs in Australia: The ETHOS Engage Study', Drug and Alcohol Review, 43, pp. 1019 - 1028, http://dx.doi.org/10.1111/dar.13828

Price O; Swanton R; Grebely J; Hajarizadeh B; Webb P; Peacock A; Dore GJ; Cowie BC; Vickerman P; Degenhardt L, 2024, 'Vaccination coverage among people who inject drugs: A systematic review', International Journal of Drug Policy, 127, http://dx.doi.org/10.1016/j.drugpo.2024.104382

Price O; Dietze P; Maher L; Dore GJ; Sutherland R; Salom C; Bruno R; Crawford S; Degenhardt L; Larney S; Peacock A, 2024, 'High COVID-19 vaccine uptake following initial hesitancy among people in Australia who inject drugs', Vaccine, 42, pp. 2877 - 2885, http://dx.doi.org/10.1016/j.vaccine.2024.03.051

Marshall AD; Willing AR; Kairouz A; Cunningham EB; Wheeler A; O'Brien N; Perera V; Ward JW; Hiebert L; Degenhardt L; Hajarizadeh B; Colledge S; Hickman M; Jawad D; Lazarus JV; Matthews GV; Scheibe A; Vickerman P; Dore GJ; Grebely J; Sargsyants N; Suleymanova L; Salkic N; Simonova M; Nemeth-Blazic T; Mravcik V; Kivimets K; Salupere R; Butsashvili M; Soselia G; Makara M; Tolmane I; Jancorienė L; Stratulat S; Flisiak R; Gheorghe L; Cernat R; Lakhov A; Stanevich O; Jarcuska P; Peck-Radosavljevic M; Robaeys G; Øvrehus A; Foster G; Sutinen J; Farkkila M; Rautiainen H; Vuoti S; Nikolova D; Pawlotsky JM; Rockstroh J; Sypsa V; Papatheodoridis G; Olafsson S; Feeney E; Teti E; Seguin-Devaux C; Pocock J; Reiff S; McDougall N; Van der Valk M; Dalgard O; Tato Marinho R; Dillon J; Peters E; Bojovic K; Matičič M; Kåberg M; Bruggmann P; Healy B; Chong VH; Yi S; Tucker J; Pasaribu LR; Tanaka J; Ashley EA; Abu Hassan MR; Mohammed NS; Chan HK; Gidaagaya S; Kyi KP; Hyung Joon K; Chin B; Baladjay PC; Kao JH; Wansom T; da Cruz B; Flower B; Ehsan E; Al Mahtab M; Khandu L; Bhadoria AS; Alavi M; KC P; Hamid S; Biryukov S; Alymbaeva D; Alaei A; Bakieva S; Flichman D, 2024, 'Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions', The Lancet Gastroenterology and Hepatology, 9, pp. 366 - 382, http://dx.doi.org/10.1016/S2468-1253(23)00335-7

Yeoh YKJ; Dore GJ; Lockart I; Danta M; Flynn C; Blackmore C; Levy MT; George J; Alavi M; Hajarizadeh B, 2024, 'Temporal change in aetiology and clinical characteristics of hepatocellular carcinoma in a large cohort of patients in New South Wales, Australia', Internal Medicine Journal, 54, pp. 602 - 612, http://dx.doi.org/10.1111/imj.16252

Bin Usman Shah SH; Alavi M; Hajarizadeh B; Matthews GV; Martinello M; Danta M; Amin J; Law MG; George J; Valerio H; Dore GJ, 2024, 'Corrigendum to “Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales” [JHEP Reports 4 (2022)] (JHEP Reports (2022) 4(10), (S2589555922001240), (10.1016/j.jhepr.2022.100552))', JHEP Reports, 6, http://dx.doi.org/10.1016/j.jhepr.2024.101022

Cheng Q; Valerio H; Cunningham EB; Shih STF; Silk D; Conway A; Treloar C; Murray C; Henderson C; Amin J; Read P; Dore GJ; Grebely J; Bath N; Milat A; Dunlop A; Holden J; Leadbeatter K; Day E; Habraken N; Dawson O; Degenhardt L; Scott C; Tillakeratne S; Marks P; Jayasinghe I; Martinez M; Reid H; Gleeson V; Van Dyk J; Mercade GE; Marshall AD; Obeid S; Wheeler A; Hooshyar SH; Catlett B; Verich A; Erratt A; Wheeler A; Ezard N; Reid D; Gorton C; Hayllar J; Lam T; Datta P; Wade A; Spruce S; Cock V; Cornwell M; Zohrab K; Christmass M; Connelly C; Cooper A; Montebello M; Cherry R; Dyer J; Arawal S; Press E; Horasak N; Lewis R; Carthew A; Morris D; Donohue K; Griffiths K; Lana JD; Shin S; Graf C; Hampson A; Qian S; Brown D; Lautier A; Curran C; Burns C; Raidu R; Stolzenhein K; Brabender W; Somes K; Abram N; Turne R; Larter S; Goodberg F; Luksza J; Hall M; Hazelwood S; Ismay C; McClurg B; Mincham C; Barlow K; Hoskins A; Salisbury K; Markham J; Talmet J; Dunn S; Mitchell A; McKinnon A; Smyth F; Snell L; Laing E; Clark M; Dorigo J, 2024, 'Health-Related Quality of Life of People Who Inject Drugs: The Enhancing Treatment of Hepatitis C in Opioid Substitution Settings Engage Study', Value in Health, 27, pp. 216 - 225, http://dx.doi.org/10.1016/j.jval.2023.10.013

Shih STF; Stone J; Martin NK; Hajarizadeh B; Cunningham EB; Kwon JA; McGrath C; Grant L; Grebely J; Dore GJ; Lloyd AR; Vickerman P; Chambers GM, 2024, 'Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination', Open Forum Infectious Diseases, 11, http://dx.doi.org/10.1093/ofid/ofad637

Chaganti J; Poudel G; Cysique LA; Dore GJ; Kelleher A; Matthews G; Darley D; Byrne A; Jakabek D; Zhang X; Lewis M; Jha N; Brew BJ, 2024, 'Blood brain barrier disruption and glutamatergic excitotoxicity in post-acute sequelae of SARS COV-2 infection cognitive impairment: potential biomarkers and a window into pathogenesis', Frontiers in Neurology, 15, http://dx.doi.org/10.3389/fneur.2024.1350848

Bah R; Sheehan Y; Li X; Price N; Butler T; Dore GJ; Grebely J; Lloyd AR; Hajarizadeh B, 2024, 'Challenges and facilitators in repeated bio-behavioural surveys for blood-borne virus infections in Australian prisons', International Journal of Drug Policy, http://dx.doi.org/10.1016/j.drugpo.2024.104401

Hajarizadeh B; Carson JM; Byrne M; Grebely J; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Lloyd AR; Dore GJ, 2024, 'Incidence of hepatitis C virus infection in the prison setting: The SToP-C study', Journal of Viral Hepatitis, 31, pp. 21 - 34, http://dx.doi.org/10.1111/jvh.13895

Grebely J; Matthews S; Causer LM; Feld JJ; Cunningham P; Dore GJ; Applegate TL, 2024, 'We have reached single-visit testing, diagnosis, and treatment for hepatitis C infection, now what?', Expert Review of Molecular Diagnostics, 24, pp. 177 - 191, http://dx.doi.org/10.1080/14737159.2023.2292645

Shah SHBU; Valerio H; Hajarizadeh B; Matthews G; Alavi M; Dore GJ, 2023, 'Cascade of care among people with hepatitis B in New South Wales, Australia', Journal of Viral Hepatitis, 30, pp. 926 - 938, http://dx.doi.org/10.1111/jvh.13881

Hajarizadeh B; Kairouz A; Ottaviano S; Ireland J; Willing A; Cunningham E; Webb P; Colledge-Frisby S; Wheeler A; Leung J; Tran LT; Price O; Vickerman P; Farrell M; Hickman M; Dore GJ; Bergenström A; Degenhardt L; Grebely J, 2023, 'Global, regional, and country-level coverage of testing and treatment for HIV and hepatitis C infection among people who inject drugs: a systematic review', The Lancet Global Health, 11, pp. e1885 - e1898, http://dx.doi.org/10.1016/S2214-109X(23)00461-8

Back to profile page